NEWS: AUGUST 2004

-8/31/2004-

FDA grants fast track status to New River Pharmaceuticals Inc.'s NRP104 for treatment of cocaine dependence. To read article click here.

Chiron Corp. to acquire Prion Solutions Inc. To read article click here.

diaDexus reports levated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) are an independent marker to coronary artery disease. To read article click here.

Micrologix Biotech Inc. acquires MitoKor Inc. To read article click here.

SEQUENOM, Inc. and the Translational Genomics Research Institute for oncology collaboration. To read article click here.

-8/30/2004-

MedImmune Inc.'s cancels Phase II clinical trials of Vitaxin® for arthritis and psoriasis treatment. To read article click here.

ZymoGenetics to initiate Phase 1b clinical trials of TACI-Ig for rheumatoid arthritis treatment. To read article click here.

Corus Pharma Inc. goes IPO. To read article click here.

-8/13/2004-

Press Release: Available from Genevac are a range of innovative solid aluminium heat transfer plates precision engineered to fit closely to a wide range of microplates. To read press release click here. Genevac Ltd. provides high-throughput centrifugal evaporation systems for combinatorial chemistry, high-throughput screening (HTS) and drug discovery. To read a review of Genevac's systems here at CombiChem Lab click here.

Press Release: Tecan, a leading player in the fast-growing Life Science product industry, will demonstrate a range of new, breakthrough products on stand A132 at International Biotech and Lab Automation Europe 2004 in London (November 16th - 17th). To read press release click here.

Amgen Inc. completes the acquisition of Tularik Inc. To read article click here.

King Pharmaceuticals Inc. and Palatin Technologies Inc. sign agreement on melanocortin receptor agonist PT-141 for the treatment of sexual dysfunction. To read article click here.

FDA announces warning that Genentech Inc.'s anti colon cancer compound Avastin can increase the risk of serious blood clots. To read article click here.

-8/12/2004-

The Strategic Research Institute (SRI) will host the "2nd Annual Nucleic Acid World Summit" conference on October 4-6, 2004, in Boston, MA. To read article click here. SRI promotes and hosts a broad range of scientific oriented conferences. For more information on SRI here at CombiChem Lab click here.

FDA approves approved Shire Pharmaceuticals' ADDERALL XR® for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. To read article click here.

The Commission of the European Communities gives Discovery Laboratories Inc.'s Surfaxin® orphan drug status. To read article click here.

Biotech Holdings' diabetes drug Sucanon to be available in Mexico in September 2004. To read article click here.

FDA grants Pharmos Corporation's neuroprotective agent Dexanabinol orphan status. To read article click here.

Illumina Inc. to generate over 25 million mouse genotypes for The Wellcome Trust Centre for Human Genetics at Oxford University. To read article click here.

Cephalon Inc. completes the acquisition of CIMA LABS Inc. To read article click here.

BioMarin Pharmaceutical Inc.'s CEO resigns. To read article click here.

Invitrogen Corporation and Exelixis Inc. form drug discovery collaboration. To read article click here.

Avigen Inc. to initiate Phase I clinical trials of AV201 for the treatment of Parkinson's disease. To read article click here.

-8/11/2004-

Press Release: Announced at the recent International Congress of Immunology in Montreal (Canada) the new Guava EasyCyte™ system makes single-cell analysis with accurate cell enumeration more versatile and easier than ever before. To read press release click here.

Press Release: Guava Technologies Inc., has announced the appointment of David A. King, Ph.D., to the position of vice president, Product Development. To read press release click here.

Isis Pharmaceuticals' antisense compound ISIS 301012 interferes with the apoB-10 protein lowering cholesterol levels. To read article click here.

Nymox Pharmaceutical Corporation to initiate Phase II clinical trials of NX-1207 benign prostatic hyperplasia. To read article click here.

MedImmune Inc.'s research shows a relationship betweeen elevated levels of EphA2 with ovarian cancer progression. To read article click here.

-8/10/2004-

Bradley Pharmaceuticals Inc. acquires Bioglan Pharmaceuticals Co. To read article click here.

Barrier Therapeutics Inc. announces positive results of Phase III clinical trials of Zimycan™. To read article click here.

Array BioPharma Inc. and QLT Inc. form small molecule drug discovery collaboration for QLT's cancer targets. To read article click here.

Nabi Biopharmaceuticals receives U.S. patent 6,756,361 entitled "Enterococcus Antigens and Vaccines". To read article click here.

Roche and Memory Pharmaceuticals Corp. extent PDE4 research collaboration. To read article click here.

Barr Pharmaceuticals Inc. and Cephalon Inc. sign agreement for the manufacture generic version of Cephalon's Actiq®. To read article click here.

Alkermes Inc. and Eli Lilly and Company to go ahead with the development of an inhaled formulation of insulin. To read article click here.

-8/09/2004-

AaiPharma to cut 125 jobs (a bit more than 10%) of its work force. To read article click here.

Archemix Corp. and Nuvelo Inc. to initiate Phase I clinical trials of thrombin inhibitor ARC183. To read article click here.

-8/06/2004-

Angiotech Pharmaceuticals Inc. acquires NeuColl Inc. for about $13 million. To read article click here.

Elite Pharmaceuticals Inc. and Nostrum Pharmaceuticals Inc. terminate negotiation talks. To read article click here.

Zyomyx Inc. receives 5 U.S. new patents. To read article click here.

-8/05/2004-

Merck & Co. Inc. signs a $335 million agreement with Dov Pharmaceutical Inc. to develop and commercialize depression drugs. To read article click here.

EPIX Medical Inc. to initiate Phase I clinical trials of injectable MRI contrast agent EP-2104R for blood clots. To read article click here.

United States court invalids Novo Nordisk's U.S. Patent No. 5,633,352 relating to recombinant human growth hormone. To read article click here.

Cytogen Corp. to initiate a clinical trials of QUADRAMET™ (samarium Sm-153 lexidronam injection) in combination with docetaxel (Taxotere®) for the treatment of hormone refractory prostate cancer. To read article click here.

-8/04/2004-

Bristol-Myers Squibb Co. to pay $150 million to settle civil fraud case by the SEC. To read article click here.

Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc.'s anticancer drug candidate BAY 43-9006 receives orphan drug status in Europe for the treatment of renal cell carcinoma. To read article click here.

Keryx Biopharmaceuticals Inc. to evaluate its oral AKT inhibitor KRX-0401 (Perifosine) in combination therapy with Gemcitabine (Gemzar®). To read article click here.

Immtech International Inc. goes IPO. To read article click here.

-8/03/2004-

FDA grants Allos Therapeutics' lead clinical candidate EFAPROXYN™ (efaproxiral) orphan drug status. To read article click here.

Alnylam Pharmaceuticals Inc. and Hybridon Inc. sign alliance for vascular endothelial growth factor (VEGF) research. To read article click here.

FDA grants Myogen Inc.'s Ambrisentan orphan drug status for the treatment of pulmonary arterial hypertension. To read article click here.

Oscient Pharmaceuticals Corp. to change its NASDAQ ticker to OSCI. To read article click here.

Valeant Pharmaceuticals initiates Phase II clinical trials of remofovir mesylate for chronic hepatitis B. To read article click here.

-8/02/2004-

U.S. regulators approve two AIDS drug combinations. To read article click here.

Cambrex Corp. appoints John R. Leone as president and CEO. To read article click here.

OSI Pharmaceuticals Inc. and Genentech Inc. file NDA to the FDA for their anti-cancer drug Tarceva. To read article click here.

Enzon Pharmaceuticals Inc. and Nektar Therapeutics sign PEG technology agreement. To read article click here.

FDA approves Gilead Sciences Inc.'s anti-HIV medication Truvada. To read article click here.

Rigel Pharmaceuticals Inc.'s Phase II clinical trials of R112 for allergic rhinitis gives positive results. To read article click here.